Skyepharma shares surge
Skyepharma plc said on Thursday, August 28, that it is close to a deal on renegotiating its convertible bonds, sending the company's shares 20 percent higher.
Ark Therapeutics H1 loss narrows
Ark Therapeutics Group plc has reported a loss after tax of £9.17 million or four pence per share for the six months ended 30 June 2008.
Care Aspirations bought by GI Partners
The UK's biggest care services firm for adults with severe learning disabilities has been bought by Anglo-American buyout firm GI Partners for an undisclosed fee.
Cinven drops out of EDT race
The number of bidders for Elan Drug Technologies has fallen after Cinven, the private equity house, pulled out of the auction.
AstraZeneca to seek compensation for Impax, Apotex
AstraZeneca plc has won the right to seek compensation from Impax Laboratories and Apotex for some of the sales it lost to their generic versions of its ulcer drug Prilosec.
New cancer treatment revealed
Scientists from Durham University and the North East England Stem Cell Institute have developed a new way of spotting bowel cancer, research published today, August 20, has revealed.